Transforming growth factor downregulates homologous recombination repair genes and increases PARP inhibitor sensitivity in BRCA2 wild-type epithelial ovarian cancer cellsAlexandre M, Lin Z, Hanna R, Ratner E. Transforming growth factor downregulates homologous recombination repair genes and increases PARP inhibitor sensitivity in BRCA2 wild-type epithelial ovarian cancer cells Gynecologic Oncology 2018, 149: 69. DOI: 10.1016/j.ygyno.2018.04.156.
Triapine-olaparib combination therapy deters peritoneal progression of PARP inhibitor-resistant epithelial ovarian cancerLin Z, Zhu Y, Huang P, Ratner E. Triapine-olaparib combination therapy deters peritoneal progression of PARP inhibitor-resistant epithelial ovarian cancer Gynecologic Oncology 2018, 149: 74. DOI: 10.1016/j.ygyno.2018.04.168.
Combination of triapine, olaparib, and cediranib for epithelial ovarian cancer therapy.Lin Z, Zhu Y, Schwartz P, Ratner E. Combination of triapine, olaparib, and cediranib for epithelial ovarian cancer therapy. Journal Of Clinical Oncology 2018, 36: e17551-e17551. DOI: 10.1200/jco.2018.36.15_suppl.e17551.
Abstract 850: The Pi3K/Akt pathway mediates epithelial-mesenchymal transition (EMT) and malignant progression in BRCA-defective epithelial ovarian cancerAlexandre M, Lin Z, Ratner E. Abstract 850: The Pi3K/Akt pathway mediates epithelial-mesenchymal transition (EMT) and malignant progression in BRCA-defective epithelial ovarian cancer Cancer Research 2017, 77: 850-850. DOI: 10.1158/1538-7445.am2017-850.
Antitumor activity of the ribonucleotide reductase inhibitor Triapine alone or in combination with paclitaxelIshiguro K, Lin Z, Rutherford T, Ratner E. Antitumor activity of the ribonucleotide reductase inhibitor Triapine alone or in combination with paclitaxel Gynecologic Oncology 2015, 137: 79. DOI: 10.1016/j.ygyno.2015.01.193.
MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapyWhicker M, Lin Z, Sartorelli A, Ratner E. MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapy Gynecologic Oncology 2014, 133: 86-87. DOI: 10.1016/j.ygyno.2014.03.231.
Abstract 3277: Pifithrin-α and veliparib synergize in the sensitization of p53 wild-type ovarian cells to cisplatin therapy.Whicker M, Liang B, Lin Z, Sartorelli A, Ratner E. Abstract 3277: Pifithrin-α and veliparib synergize in the sensitization of p53 wild-type ovarian cells to cisplatin therapy. Cancer Research 2013, 73: 3277-3277. DOI: 10.1158/1538-7445.am2013-3277.
Abstract 4490: Triapine sensitizes chemoresistant ovarian cancer cells to platinum therapy.Ratner E, Whicker M, Lin Z, Sartorelli A. Abstract 4490: Triapine sensitizes chemoresistant ovarian cancer cells to platinum therapy. Cancer Research 2013, 73: 4490-4490. DOI: 10.1158/1538-7445.am2013-4490.
Targeting the upregulation of the AKT pathway and homologous recombination repair as a therapeutic strategy for epithelial ovarian cancer.Ratner E, Lin Z, Rutherford T, Azodi M, Santin A, Schwartz P, Sartorelli A. Targeting the upregulation of the AKT pathway and homologous recombination repair as a therapeutic strategy for epithelial ovarian cancer. Journal Of Clinical Oncology 2012, 30: e13125-e13125. DOI: 10.1200/jco.2012.30.15_suppl.e13125.
Abstract 2743: Triapine sensitizes ovarian cancer cells to platinum drugs and PARP inhibitorsLin Z, Ratner E, Sartorelli A. Abstract 2743: Triapine sensitizes ovarian cancer cells to platinum drugs and PARP inhibitors Cancer Research 2012, 72: 2743-2743. DOI: 10.1158/1538-7445.am2012-2743.